The novel persistent sodium current inhibitor PRAX‐562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers

Abstract

PRAX-562 demonstrated robust preclinical anticonvulsant activity similar to CBZ but improved compared to LTG. PRAX-562 exhibited significantly improved preclinical tolerability compared with standard Na_V blockers (CBZ and LTG), potentially due to the preference for persistent I_Na . Preferential targeting of persistent I_Na may represent a differentiated therapeutic option for diseases of hyperexcitability, where standard Na_V blockers have demonstrated efficacy but poor tolerability.